The Royal Marsden NHS Foundation Trust, Downs Road, Sutton
Welcome,         Profile    Billing    Logout  
 3 Trials 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cunningham, ssor David
PLATFORM, NCT02678182: Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Active, not recruiting
2
494
Europe
Capecitabine, MEDI4736 (Durvalumab), Trastuzumab, Rucaparib, Ramucirumab
Royal Marsden NHS Foundation Trust, MedImmune LLC, Clovis Oncology, Inc., Eli Lilly and Company, AstraZeneca
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
03/25
06/27
Patel, Bijal
PRIOH-1, NCT03073967 / 2020-004940-27: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Recruiting
3
153
Europe, Canada, US, RoW
Pritelivir, Investigator's choice, Foscarnet or Cidofovir or Imiquimod
AiCuris Anti-infective Cures AG, Medpace, Inc.
HSV Infection
07/25
11/25
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
More
Recruiting
3
330
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
PLATFORM, NCT02678182: Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Active, not recruiting
2
494
Europe
Capecitabine, MEDI4736 (Durvalumab), Trastuzumab, Rucaparib, Ramucirumab
Royal Marsden NHS Foundation Trust, MedImmune LLC, Clovis Oncology, Inc., Eli Lilly and Company, AstraZeneca
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
03/25
06/27
NCT04440735: A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Active, not recruiting
1/2
125
US
DSP107, Atezolizumab
Kahr Medical
Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
09/25
09/25
NCT03840460: A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers

Recruiting
N/A
200
Europe
Royal Marsden NHS Foundation Trust
Pancreatic Adenocarcinoma
01/23
01/23

Download Options